What were the key takeaways from Heron Therapeutics’s earnings call?

What factors drove the changes in Heron Therapeutics's revenue and profit?

What is the revenue and EPS growth rate for Heron Therapeutics year over year?

What were the key takeaways from Heron Therapeutics's earnings call?

What is Heron Therapeutics's gross profit margin?

What is Heron Therapeutics's latest dividend and current dividend yield?

What does Heron Therapeutics do and what are its main business segments?

Did Heron Therapeutics beat or miss consensus estimates last quarter?

- **Revenue Growth**: 2025 net product sales of $154.9 million, with ZYNRELEF up 48% YoY and APONVIE up 97% YoY.
- **EBITDA Performance**: Adjusted EBITDA of $14.7 million, doubling prior year and exceeding guidance.
- **Acute Care Momentum**: Q4 2025 Acute Care portfolio grew 57% YoY, driven by CrossLink IGNITE, VAN, and J-Code initiatives.
- **Strategic Investments**: 2026 focus on high-opportunity geographies, targeting EBITDA of $10-$20 million despite near-term growth investments.
- **Regulatory Tailwinds**: NOPAIN Act and APONVIE guidelines to support long-term adoption and revenue acceleration.

**【CEO Summary Section】**
- **Revenue Growth and Financial Health**: Total net product sales reached $154.9 million in 2025, driven by a 48% YoY revenue increase in ZYNRELEF. Adjusted EBITDA was $14.7 million, exceeding guidance and doubling the prior year's performance.
- **Acute Care Momentum**: Q4 2025 saw ZYNRELEF grow 48% YoY and APONVIE grow 97% YoY, with the Acute Care portfolio increasing 57% YoY. Strategic initiatives like the CrossLink IGNITE program, VAN rollout, and new J-Codes (J0668 for ZYNRELEF, J8502 for APONVIE) reduced friction and boosted adoption.
- **2026 Strategy**: Plans to expand commercial teams in high-opportunity geographies, temporarily moderating EBITDA growth but positioning for long-term revenue acceleration. Prefilled syringe (PFS) development for ZYNRELEF targets FDA approval in mid- to late 2027.

**【CFO Financial Commentary】**
- **2025 Financial Highlights**: Gross margin of 73%, reflecting cost discipline. Oncology franchise generated $105 million in net revenue, with CINVANTI remaining resilient despite SUSTOL wind-down.
- **2026 Guidance**: Net product sales of $173-$183 million and adjusted EBITDA of $10-$20 million, balancing growth investments with profitability.

**【Q&A Key Highlights】**
- **NOPAIN Act Impact**: Expected tailwind for ZYNRELEF as hospitals adopt post-op pain reimbursement clarity. CrossLink IGNITE program and J-Code simplification accelerate adoption.
- **Litigation Update**: Slayback litigation in Delaware District Court awaiting decision; confident in case strength. 30-month stay on generics applies.
- **APONVIE Guidelines**: Fifth Consensus Guidelines inclusion to drive P&amp;T approvals and sustained growth, with impact expected in late 2026.
- **Commercial Execution**: VAN rollout seamless; PFS launch strategy similar to VAN, focusing on inventory management and targeted expansion.

Heron Therapeutics, Inc.(HRTX)-20260226-2025 Q4 Earnings call transcript

- **Acute Care Surge**: ZYNRELEF +49% YoY, APONVIE +173% YoY, Q3 acute care revenue $12.3M
- **J-code Win**: ZYNRELEF billing clarity drives 17% Oct unit growth
- **CINVANTI Resilience**: Stable at $24M despite competitive pressure
- **2027 PFS Launch**: Simplified delivery system targets late 2027 approval
- **Cash Position**: $55.5M post-financing, debt extinguishment costs $11.3M

**【CEO Opening Remarks】**
- **Q3 2025 Financial Highlights**: Total revenue $38.2M (YoY +15%), adjusted EBITDA $1.5M, gross margin 68.8% (down 2.4pts YoY due to one-time inventory write-off). 
- **Product Momentum**: ZYNRELEF net sales $9.3M (YoY +49%), APONVIE $3M (YoY +173%). CINVANTI stable at $24M, SUSTOL declining to $1.9M (YoY -32%).
- **Strategic Wins**: J-code for ZYNRELEF effective Oct 1, prefilled syringe (PFS) approval targeted for late 2027.
- **Operational Focus**: Post-financing, management prioritizing commercial execution and product growth.

**【COO Operational Update】**
- **ZYNRELEF Growth Drivers**: 
  - 200mg vial access needle (VAN) adoption
  - CrossLink Ignite distributor incentive program
  - Dedicated IBM team
  - Q3 units: 1,127/day (vs 882/day YoY), 17% Oct YoY surge
- **APONVIE Expansion**: 
  - 6-person dedicated team launched July 2025
  - Q3 units: 998/day (vs 418/day YoY)
  - 2025 PONV guidelines expected Q4
- **CINVANTI Synergy**: APONVIE pull-through driving CINVANTI orders in shared accounts

**【CFO Financial Review】**
- **Revenue**: Acute care $12.3M (QoQ +15%), oncology $25.9M (QoQ +1%)
- **Gross Profit**: $26.3M (68.8% margin), adjusted for $1.4M inventory write-off
- **Expenses**: 
  - SG&A $26.9M (YoY +15%)
  - R&D $3.5M (YoY -22%)
  - Net loss $17.5M (YoY +263% due to $11.3M debt extinguishment)
- **Cash Position**: $55.5M post-Q3 financing

**【Q&A Highlights】**
1. **ZYNRELEF October Momentum**: 17-18% MoM unit growth in first 2 weeks
2. **Gross Margin Adjustment**: Excluding write-off, adjusted margin ~74.5%
3. **NOPAIN Act Impact**: 75% of ZYNRELEF procedures now reimbursable
4. **2026 Commercial Investment**: Contingent on Q4 performance, potential team expansion
5. **SUSTOL Winddown**: Plan to halt commercialization by Q4 2026

Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript

- **Financial Strength**: $150M credit facility and $35M convertible notes enhance liquidity, reducing net loss to $2.4M Q2.
- **Revenue Growth**: Q2 net revenue $37.2M, H1 $76.1M; ZYNRELEF demand up 6.3%, APONVIE +19%.
- **J-code Impact**: Effective Oct 1, simplifying reimbursement and supporting ZYNRELEF adoption.
- **Oncology Resilience**: $26.5M Q2, maintaining market share in competitive markets.
- **Guidance Update**: 2025 EBITDA revised to $9-13M, reflecting cost management and growth initiatives.

**【CEO Summary Section】**
- **Successful Financing**: Secured $150M credit facility, $35M convertible notes, and $28M equity, reducing debt and enhancing liquidity.
- **Q2 Financials**: Net revenue $37.2M, H1 $76.1M; adjusted EBITDA $7.9M (H1). Oncology franchise contributed $26.5M Q2.
- **Product Momentum**: ZYNRELEF demand units +6.3% QoQ, APONVIE +19% demand growth; J-code for ZYNRELEF effective Oct 1.
- **Strategic Initiatives**: Restructured sales teams, enhanced CrossLink incentives, and clinical educator support for ZYNRELEF.

**【COO Product Performance】**
- **ZYNRELEF**: Q2 net $10.7M (+55.5% YOY), 700+ accounts. Inventory drawdown reduced sales by $400K, expected normalization in Q3.
- **APONVIE**: Q2 demand +19%, revenue +9% despite 340B discounts; new 6-rep team launched.
- **Oncology**: $26.5M Q2, maintaining market share in competitive landscape.

**【CFO Financial Commentary】**
- **Gross Profit**: $27.3M (73.5%), up from 70.8% YOY, driven by volume growth.
- **Cost Management**: SG&A down $1.8M (Q2) and $3.5M (H1), R&D down $1.2M (Q2) and $2M (H1).
- **Net Loss**: $2.4M Q2, H1 net income $300K; cash $40.6M post-refinancing.
- **Guidance**: 2025 revenue $153-163M, EBITDA $9-13M.

**【Q&A Highlights】**
- **ZYNRELEF Transition**: Q2 impact $400K, Q3 normalization expected; J-code to streamline reimbursement.
- **Sales Force Restructure**: Separate ZYNRELEF and APONVIE teams; CrossLink incentives for targeted accounts.
- **NOPAIN Act**: Early signs of shifted payer conversations, potential long-term growth.
- **Refinancing Details**: Credit facility rate ~10%, net cash $11-12M post-closing.
- **Share Impact**: Pro forma shares ~183M common, 208M including convertibles.

Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript

- **Q1 2025 Financial Highlights**: $39 million revenue, $6.2 million adjusted EBITDA, and $2.6 million net income reflect strong operational execution.
- **Product Growth Drivers**: ZYNRELEF (+60% YoY) and APONVIE (+432% YoY) outpace market trends, supported by formulary wins and Crosslink partnerships.
- **Strategic Moves**: Settlement with Mylan, Mark Hensley leadership addition, and revised EBITDA guidance ($4M–$12M) signal confidence in 2025 growth.
- **Key Risks & Opportunities**: Mid-70s gross margin stability, oncology franchise resilience, and APONVIE's multi-hundred-million-dollar potential.


**【CEO Summary Section】**
- Total net revenue for Q1 2025: $39 million, with record quarterly adjusted EBITDA of $6.2 million and net income of $2.6 million.
- Oncology franchise (CINVANTI and SUSTOL) combined net revenue: $28.6 million, maintaining market share in a competitive environment.
- ZYNRELEF and APONVIE growth: Q1 2025 sales up 60% and 432% YoY, respectively, driven by expanded formulary access and partnerships.
- Key initiatives: Crosslink partnership integration, new commercial leader Mark Hensley hire, and settlement with Mylan Pharmaceuticals to avoid litigation costs.
- 2025 focus: disciplined execution, commercial performance optimization, and selective team expansion for high-return growth.

**【CFO Financial Commentary】**
- Product gross profit margin: 78% (Q1 2025), up from 76% YoY, due to production efficiencies.
- G&A expenses: $25 million (down 5.3% YoY) due to cost restructuring, offset by increased sales and marketing spend.
- R&D expenses: $2.3 million (down 49.8% YoY) due to reduced personnel costs and development activities.
- Cash and short-term investments: $50.7 million as of March 31, 2025.
- Adjusted EBITDA guidance revised to $4 million–$12 million for 2025, up from prior range of $0–$8 million.

**【Q&A Key Takeaways】**
- **Litigation Settlement**: Positive impact on near-term financials through reduced legal expenses and improved cash flow visibility.
- **ZYNRELEF Momentum**: 5 new accounts in onboarding phase, with expected inflection in Q3/Q4 2025 as Crosslink partnership drives pull-through.
- **APONVIE Growth**: Potential for multi-hundred-million-dollar peak sales, leveraging unique safety profile and third-line agent positioning.
- **Gross Margin Trends**: Mid-70s range expected for 2025, with minor fluctuations based on manufacturer scale economics.


Heron Therapeutics (HRTX)-6 May 25-2025 Q1 Earnings call transcript

- **Record 2024 performance**: $144.2M net revenue (+14% YoY), first-year profitability, and $8.5M ZYNRELEF Q4 sales (33% QoQ growth).
- **Strategic wins**: VAN launch saves 15+ accounts, NOPAIN Act expansion, and 800 CrossLink reps driving 30%+ growth in key accounts.
- **Financial strength**: 73.2% gross margin, $59.3M cash, and 2025 guidance of $153-163M revenue with $0-8M EBITDA.
- **Pipeline momentum**: Prefilled syringe for ZYNRELEF on track for 2026/2027 launch, and patent victory secures CINVANTI through 2035.

**【CEO Opening Remarks】**
- Achieved **$144.2 million in net revenue for 2024**, up 14% YoY, with **$3.6 million net income in Q4** and full-year profitability.
- **ZYNRELEF net revenue reached $8.5 million in Q4 (33% QoQ growth)**, driven by expanded labeling, CrossLink partnership, and NOPAIN Act inclusion.
- **CINVANTI rebounded to $26.9 million in Q4**, up from $22.7 million in Q3, with full-year revenue of $100 million (+6% YoY).
- Launched the **Vial Access Needle (VAN)** in mid-December, receiving positive feedback and saving 15+ accounts post-launch.
- Secured patent victory against Fresenius Kabi, with patents expiring in 2035, and reduced operating expenses by $80 million since 2022.

**【CFO Financial Update】**
- **Gross margin improved to 73.2% in 2024 (from 48.8% in 2023)**, with product gross profit up 71% to $105.6 million.
- **SG&A expenses decreased 25% YoY to $100.5 million**, driven by headcount reductions and cost efficiencies.
- **2025 guidance: $153-163 million net revenue** and **$0-8 million adjusted EBITDA**, with potential lumpiness due to legal expenses and PFS spend.
- Ended 2024 with **$59.3 million in cash**, excluding $4.7 million in inventory/write-off charges.

**【Q&A Highlights】**
- **ZYNRELEF momentum**: CrossLink reps (800+) are driving 30% higher growth in overlapping accounts; 200mg VAN launch in April will accelerate adoption.
- **NOPAIN Act impact**: April 2025 implementation will expand reimbursement, aligning with 310% YoY growth in APONVIE and 48% in ZYNRELEF.
- **Cash flow outlook**: 2025 may see quarterly fluctuations due to legal expenses, but core business is stable with conservative CINVANTI ASP guidance.
- **Pipeline progress**: Prefilled syringe for ZYNRELEF in development, targeting late 2026/early 2027 launch, with stable demo batch results.
- **Debt discussions**: Baker Brothers engagement expected in Q2 2025, with Fresenius patent clarity improving dialogue.

Heron Therapeutics (HRTX)-27 Feb 25-2024 Q4 Earnings call transcript

Heron Therapeutics (HRTX)-12 Nov 24-2024 Q3 Earnings call transcript

Heron Therapeutics (HRTX)-6 Aug 24-2024 Q2 Earnings call transcript

Heron Therapeutics (HRTX)-7 May 24-2024 Q1 Earnings call transcript

Heron Therapeutics (HRTX)-12 Mar 24-2023 Q4 Earnings call transcript

- **Cost Efficiency Transformation**: Operating expenses reduced by 26% in 2023, targeting $108-116 million in 2024. Gross margin set to triple from 41% (2023) to 75%+ by 2025.
- **Acute Care Breakthrough**: ZYNRELEF sales surge 48% YoY, APONVIE hits all-time highs with 156 new accounts. sNDA expansion for shoulder/spine procedures (Jan 2024) and prefilled syringe launch (Q3 2024) poised to accelerate growth.
- **Profitability Path**: EBITDA loss narrowing to $22 million in 2024, with positive EBITDA expected by Q4 2024 and $65 million+ cash balance.
- **Strategic Focus**: Orthopedic surgery focus for ZYNRELEF (60% of current business), perioperative pain/vomiting dominance with APONVIE, and partnerships to expand OR reach.

**【CEO Summary Section】**
- **Cost Reduction and Efficiency**: Operating expenses reduced from $182 million in 2022 to $135 million in 2023, with a target of $108-116 million in 2024. Gross margin improved from 41% in 2023 to 62% in 2024, targeting over 75% by 2025.
- **Product Momentum**: ZYNRELEF and APONVIE achieved all-time high unit sales in the last 8 weeks. ZYNRELEF net sales grew 48% year-over-year, driven by orthopedic procedures (60% of current business). APONVIE net sales reached $350,000 in Q3, with 156 accounts ordering post-P&T approvals.
- **Strategic Focus**: Acute Care franchise targeting the perioperative space; ZYNRELEF sNDA for shoulder and spine procedures (PDUFA date January 23, 2024) and prefilled syringe launch in Q3 2024.

**【CFO Financial Commentary】**
- **Q3 2023 Financials**: Net loss of $25 million, down from $41.9 million in Q3 2022. Gross profit $13.2 million (42% of net revenue), impacted by inventory write-offs. Operating cash burn reduced to $6 million in Q3 (from $90 million in Q1 2023).
- **2024 Guidance**: Revenue $138-158 million, gross margin 68-70%, EBITDA loss of $22 million to $3 million. Anticipated positive EBITDA by Q4 2024 with $65 million+ cash balance.

**【Q&A Highlights】**
- **Gross Margin Trajectory**: 2023 gross margin 41% (impacted by write-offs), 2024 target 68-70%, long-term 75-80% as scale benefits and new products (e.g., APONVIE 1,000kg batches) kick in.
- **ZYNRELEF Growth Drivers**: sNDA expansion adds 5-6 million procedures (70% orthopedic), prefilled syringe simplifies administration, and partnerships with medical device reps to expand OR presence.
- **Acute Care Potential**: Acute Care franchise revenue up 48% YoY, with oncology franchise (CINVANTI/SUSTOL) contributing $26.7 million in Q3 and 2023 guidance raised to $104-106 million.


Actual									-0.57	-0.61	-0.64	-0.68	-0.58	-0.62	-0.51	-0.54	-0.63	-0.55	-0.38	-0.17	-0.27	-0.35	-0.17	-0.07	-0.02	-0.06	-0.03	0.02	0.01	-0.02	-0.1	-0.02
Forecast									-0.6538	-0.6214	-0.6271	-0.6463	-0.5438	-0.558	-0.608	-0.5767	-0.485	-0.536	-0.376	-0.3167	-0.2164	-0.2233	-0.2925	-0.1538	-0.0745	-0.0393	-0.0379	-0.0306	-0.0062	-0.01	-0.015	-0.02
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+12.82%	+1.83%	-2.06%	-5.21%	-6.66%	-11.11%	+16.12%	+6.36%	-29.90%	-2.61%	-1.06%	+46.32%	-24.77%	-56.74%	+41.88%	+54.49%	+73.15%	-52.67%	+20.84%	+165.36%	+261.29%	-100.00%	-566.67%	0.00%

HRTX

HRTX fundamentals

HRTX Q4 2025 Earnings

Earnings Call

You can ask Aime

HRTX

HRTX fundamentals

HRTX Q4 2025 Earnings

Earnings Call

HRTX Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

HRTX Earnings Call Summary for Q3/20258:30 AM on Nov 4, 2025

HRTX Earnings Call Summary for Q2/20258:30 AM on Aug 8, 2025

HRTX Earnings Call Summary for Q1/20258:00 AM on May 6, 2025

HRTX Earnings Call Summary for Q4/20248:00 AM on Feb 27, 2025

You can ask Aime